Association of PTPN22 C1858T in the French type 1 diabetic case-control population
| Group . | Individuals . | Genotypes . | . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | C/C . | C/T . | T/T . | Frequency of T carrier (%) . | OR for T carrier (95% CI) . | P value (association)*† . | P value (heterogeneity)*‡ . | ||
| Control subjects | 442 | 363 | 73 | 6 | 17.9 | |||||
| Cases | ||||||||||
| All | 885 | 623 | 243 | 19 | 29.6 | 1.93 (1.46–2.56) | 4 × 10−6 | |||
| DR34− | 577 | 399 | 163 | 15 | 30.8 | 2.05 (1.52–2.77) | 2 × 10−6 | NS | ||
| DR34+ | 306 | 222 | 80 | 4 | 27.4 | 1.74 (1.23–2.47) | 0.002 | |||
| INS− | 228 | 155 | 69 | 4 | 32.0 | 2.16 (1.49–3.13) | 3 × 10−5 | NS | ||
| INS+ | 642 | 455 | 173 | 14 | 29.1 | 1.89 (1.40–2.54) | 2 × 10−5 | |||
| FT1D− | 401 | 279 | 113 | 9 | 30.4 | 2.01 (1.45–2.78) | 2 × 10−5 | NS | ||
| FT1D+ | 129 | 87 | 39 | 3 | 32.6 | 2.22 (1.43–3.45) | 0.0003 | |||
| AAB− | 200 | 138 | 59 | 3 | 31.0 | 2.06 (1.40–3.04) | 0.0002 | NS | ||
| AAB+ | 155 | 101 | 48 | 6 | 34.8 | 2.46 (1.63–3.70) | 1 × 10−5 | |||
| AID− | 249 | 170 | 74 | 5 | 31.7 | 2.13 (1.49–3.06) | 3 × 10−5 | NS | ||
| AID+ | 98 | 63 | 31 | 4 | 35.7 | 2.55 (1.58–4.12) | 9 × 10−5 | |||
| FAID− | 334 | 233 | 94 | 7 | 30.2 | 1.99 (1.42–2.79) | 5 × 10−5 | 0.05 | ||
| FAID+ | 50 | 28 | 21 | 1 | 44.0 | 3.61 (1.96–6.64) | 1 × 10−5 | |||
| Group . | Individuals . | Genotypes . | . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | C/C . | C/T . | T/T . | Frequency of T carrier (%) . | OR for T carrier (95% CI) . | P value (association)*† . | P value (heterogeneity)*‡ . | ||
| Control subjects | 442 | 363 | 73 | 6 | 17.9 | |||||
| Cases | ||||||||||
| All | 885 | 623 | 243 | 19 | 29.6 | 1.93 (1.46–2.56) | 4 × 10−6 | |||
| DR34− | 577 | 399 | 163 | 15 | 30.8 | 2.05 (1.52–2.77) | 2 × 10−6 | NS | ||
| DR34+ | 306 | 222 | 80 | 4 | 27.4 | 1.74 (1.23–2.47) | 0.002 | |||
| INS− | 228 | 155 | 69 | 4 | 32.0 | 2.16 (1.49–3.13) | 3 × 10−5 | NS | ||
| INS+ | 642 | 455 | 173 | 14 | 29.1 | 1.89 (1.40–2.54) | 2 × 10−5 | |||
| FT1D− | 401 | 279 | 113 | 9 | 30.4 | 2.01 (1.45–2.78) | 2 × 10−5 | NS | ||
| FT1D+ | 129 | 87 | 39 | 3 | 32.6 | 2.22 (1.43–3.45) | 0.0003 | |||
| AAB− | 200 | 138 | 59 | 3 | 31.0 | 2.06 (1.40–3.04) | 0.0002 | NS | ||
| AAB+ | 155 | 101 | 48 | 6 | 34.8 | 2.46 (1.63–3.70) | 1 × 10−5 | |||
| AID− | 249 | 170 | 74 | 5 | 31.7 | 2.13 (1.49–3.06) | 3 × 10−5 | NS | ||
| AID+ | 98 | 63 | 31 | 4 | 35.7 | 2.55 (1.58–4.12) | 9 × 10−5 | |||
| FAID− | 334 | 233 | 94 | 7 | 30.2 | 1.99 (1.42–2.79) | 5 × 10−5 | 0.05 | ||
| FAID+ | 50 | 28 | 21 | 1 | 44.0 | 3.61 (1.96–6.64) | 1 × 10−5 | |||
Data are n. All P values were based on two-sided χ2 tests. Contrasted risk subgroups, DR34+/DR34− (HLA-DR3/DR4 risk); INS+/INS− (INS risk); FT1D+/FT1D− (familial history of type 1 diabetes); AAB+/AAB− (presence of other autoantibodies); AID+/AID− (presence of other autoimmune diseases); and FAID+/FAID− (familial history of autoimmune diseases), are described in research design and methods.
Test of T carriers versus noncarriers.
Test of association compared with control subjects.
Test of heterogeneity between contrasted subgroups. NS, nonsignificant (P > 0.05).